Suppr超能文献

抗疟药在喀麦隆疗效演变中的耐药标志物:系统评价和荟萃分析(1998-2020 年)。

Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998-2020).

机构信息

MARCAD-DELTAS Programme, Laboratory for Public Health Research Biotechnologies, University of Yaoundé I, Yaoundé, Cameroon.

The Biotechnology Centre, University of Yaoundé I, Yaoundé, Cameroon.

出版信息

Malar J. 2021 Jan 9;20(1):32. doi: 10.1186/s12936-020-03543-8.

Abstract

BACKGROUND

Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020.

METHODS

The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran's Q and I statistics. The random effects model was used as standard in the determination of heterogeneity between studies.

RESULTS

Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1-42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected.

CONCLUSIONS

This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620.

摘要

背景

疟疾在喀麦隆仍然高度流行。药物耐药性的迅速出现和传播导致从单一疗法转向青蒿素为基础的联合疗法。本系统评价和荟萃分析旨在确定从 1998 年 1 月至 2020 年 8 月,喀麦隆抗疟药物疗效不断变化的情况下,疟原虫耐药性标志物的流行率和分布。

方法

采用 PRISMA-P 和 PRISMA 声明纳入关于疟原虫抗疟药物耐药基因(Pfcrt、Pfmdr1、Pfdhfr、Pfdhps、PfATP6、Pfcytb 和 Pfk13)单核苷酸多态性(SNP)的研究。采用 Cochran's Q 和 I 统计量评估纳入研究的异质性。在确定研究之间的异质性时,采用随机效应模型作为标准。

结果

在筛选出的 902 条记录中,有 48 项研究被纳入本次汇总的分子数据荟萃分析。对来自 47382 个样本的 18706 个抗疟药物耐药基因 SNP 进行了基因分型,总体流行率为 35.4%(95%CI 29.1-42.3%)。1998 年至 2020 年间,关键突变体(包括 Pfcrt 76T、Pfmdr1 86Y、Pfdhfr 51I、Pfdhfr 59R、Pfdhfr 108N)的流行率均显著下降(所有 P 值均<0.0001)。唯一的例外是 Pfdhps 437G,其流行率随时间增加(30.4%-46.9%,P<0.0001),而 Pfdhps 540E 则基本不变(0.0%-0.4%,P=0.201)。在探索突变体单倍型方面,研究发现 Pfcrt CVIET 混合五联单倍型的流行率从 1998 年的 57.1%显著增加到 2020 年的 57.9%(P<0.0001)。此外,在同一研究期间,三重 Pfdhfr IRN 突变体单倍型(66.2%至 67.3%,P=0.427)并未发生显著变化。与青蒿素耐药相关的 Pfk13 氨基酸多态性未检测到。

结论

本综述报告了在过去二十年中,疟原虫基因对 4-氨基喹啉和氨基醇的耐药性总体上呈下降趋势。喀麦隆的 Pfk13 基因中存在 SNP 并不意味着对青蒿素的耐药性是一个问题。系统评价注册 PROSPERO CRD42020162620。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验